fbpx

Kos Pharmaceuticals Sold for 3.7 Billion

Health care products maker Abbott Laboratories of Abbott Park, Ill., is acquiring specialty pharmaceutical company Kos Pharmaceuticals in Cranbury for $3.7 billion or $78 per share cash for all outstanding sharesHealth care products maker Abbott Laboratories (NYSE: ABT) of Abbott Park, Ill., is acquiring specialty pharmaceutical company Kos Pharmaceuticals (Nasdaq: KOSP) in Cranbury for $3.7 billion or $78 per share cash for all outstanding shares. Kos develops proprietary medications for chronic cardiovascular, metabolic and respiratory diseases.

Abbott is buying Kos to expand in the cholesterol-management market in which the company has two key products: Niaspan is a niacin product for raising so-called good-cholesterol levels and Advicor, a treatment for patients with multiple lipid disorders. Kos has other products in development to treat lipid disorders. Shares of Kos Pharmaceuticals leaped $26.85 to $76.94 in morning trading after word of the deal got out.

NJBIZ Business Events

Healthcare Heroes 2020

Thursday, October 15, 2020
Healthcare Heroes 2020

Forty Under 40 Awards 2020

Wednesday, October 28, 2020
Forty Under 40 Awards 2020

Digi-Tech Innovator Awards 2020

Thursday, November 12, 2020
Digi-Tech Innovator Awards 2020